Calidi director granted 5,000 stock options at $1.36
Calidi Biotherapeutics, Inc. (CLDI) reported that director James A. Schoeneck received a grant of 5,000 non-qualified stock options on August 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Calidi Biotherapeutics, Inc. (CLDI) reported that director James A. Schoeneck received a grant of 5,000 non-qualified stock options on August 17, 2026. The options have an exercise price of $1.36 per share, vest in 1/12th monthly over one year, expire on August 17, 2036, and were issued under Calidi’s 2023 Equity Incentive Plan pursuant to its non-employee director compensation policy. Following this grant, Schoeneck holds 5,000 options reported here, which do not include options previously granted.
Insider Trade Summary
Grant/Award: 5,000 shares
Grant/Award
1 txn
Insider
Schoeneck James A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 5,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Options (right to buy) — 5,000 contracts (Direct)
Footnotes (2)
- F1. On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
- F2. Does not include the stock options previously granted to the Reporting Person.
Key Figures
Options granted: 5,000 options
Exercise price: $1.36 per share
Underlying shares: 5,000 shares
+2 more
5 metrics
Options granted
5,000 options
Non-qualified stock options granted to director on August 17, 2026
Exercise price
$1.36 per share
Exercise price of options, equal to closing price on grant date August 17, 2026
Underlying shares
5,000 shares
Common stock underlying the non-qualified stock options granted
Expiration date
August 17, 2036
Expiration of the non-qualified stock options granted to the director
Post-transaction derivative holdings (this grant)
5,000 options
Options held directly after transaction, excluding previously granted options
Key Terms
Non-Qualified Stock Options, exercise price, vest, Equity Incentive Plan
4 terms
Non-Qualified Stock Options financial
"the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise price financial
"at an exercise price of $1.36 per share (equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"and shall vest, and become exercisable, in 1/12th per month installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Equity Incentive Plan financial
"issued under the Issuer's 2023 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did CLDI director James A. Schoeneck report on this Form 4?
Director James A. Schoeneck reported receiving a grant of 5,000 non-qualified stock options in Calidi Biotherapeutics, Inc. These options are part of his compensation as a non-employee director under Calidi’s 2023 Equity Incentive Plan.
How many CLDI stock options were granted to James A. Schoeneck and at what price?
James A. Schoeneck was granted 5,000 non-qualified stock options at an exercise price of $1.36 per share. The footnote states this price equals the closing price on the August 17, 2026 grant date.
What is the vesting schedule of the 5,000 CLDI options granted to James A. Schoeneck?
The 5,000 options vest and become exercisable in 1/12th per month over one year starting on the August 17, 2026 grant date. This creates monthly vesting installments throughout the first year after grant.
When do James A. Schoeneck’s CLDI stock options expire?
The non-qualified stock options granted to James A. Schoeneck expire on August 17, 2036. After this 10-year term, any unexercised options from this grant will no longer be exercisable.
Under which plan were the CLDI options to James A. Schoeneck granted?
These options were granted under Calidi Biotherapeutics’ 2023 Equity Incentive Plan as part of its non-employee director compensation policy. The plan governs equity awards, including this non-qualified stock option grant.
How many CLDI options does James A. Schoeneck hold after this reported grant?
After this transaction, James A. Schoeneck holds 5,000 options from this grant, held directly. A footnote clarifies that this does not include stock options previously granted to him, which are not quantified here.
AI-generated analysis. How Rhea-AI works. Not financial advice.
